CN114432541A - Cosmetic injection method adopting injection and lifting in front of ears - Google Patents
Cosmetic injection method adopting injection and lifting in front of ears Download PDFInfo
- Publication number
- CN114432541A CN114432541A CN202210076346.4A CN202210076346A CN114432541A CN 114432541 A CN114432541 A CN 114432541A CN 202210076346 A CN202210076346 A CN 202210076346A CN 114432541 A CN114432541 A CN 114432541A
- Authority
- CN
- China
- Prior art keywords
- polymer carrier
- ear
- degradable high
- needle
- area
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 49
- 239000007924 injection Substances 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000002537 cosmetic Substances 0.000 title claims abstract description 18
- 210000005069 ears Anatomy 0.000 title claims abstract description 8
- 229920000642 polymer Polymers 0.000 claims abstract description 57
- 239000002131 composite material Substances 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 238000004140 cleaning Methods 0.000 claims abstract description 13
- 206010033675 panniculitis Diseases 0.000 claims abstract description 11
- 210000004304 subcutaneous tissue Anatomy 0.000 claims abstract description 11
- 238000005520 cutting process Methods 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 4
- 210000001519 tissue Anatomy 0.000 claims description 15
- 239000000945 filler Substances 0.000 claims description 14
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 241000746998 Tragus Species 0.000 claims description 6
- 230000001815 facial effect Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 3
- 239000002612 dispersion medium Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- 238000010561 standard procedure Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229920006237 degradable polymer Polymers 0.000 claims 3
- 229920002988 biodegradable polymer Polymers 0.000 claims 2
- 239000004621 biodegradable polymer Substances 0.000 claims 2
- 235000002961 Aloe barbadensis Nutrition 0.000 claims 1
- 244000186892 Aloe vera Species 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 235000011399 aloe vera Nutrition 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000003796 beauty Effects 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940006091 aloe polysaccharide Drugs 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000021401 Facial Nerve injury Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a cosmetic injection method adopting injection pulling in front of ears, which comprises the following steps: cleaning the front outline of the ear and completing the standard operation process; dividing the front outline of the ear by adopting the principle of three-axis diagonal plane line shape; preparing a composite degradable high-molecular polymer carrier; injecting a composite degradable high polymer carrier to the treatment positions of the front outline of the left ear and the front outline of the right ear in a mode of obliquely inserting a needle head; when the compound degradable high molecular polymer carrier is injected, the compound degradable high molecular polymer carrier is evenly pushed into the subcutaneous tissue of the skin of a human body by obliquely cutting each axis point on two sides of the preset direction by 30 to 40 degrees of angle of the needle head, and the needle head adopts a blunt needle mode. Has the advantages that: the effects of immediately improving the grain of the statute and the grain of the puppet and changing the relaxation are safe and effective, and the curative effect can be maintained for about 1 year and half to 2 years.
Description
Technical Field
The invention relates to the field of micro-plastic cosmetology, in particular to a cosmetic injection method adopting injection lifting in front of ears, which is assisted by the principle of three-axis diagonal plane linearity, and carries out uniform injection on a composite degradable high polymer carrier from a treatment position of the front outline of the ears at each axial line point on two sides of a preset direction, thereby realizing the effects of improving skin wrinkles and increasing the elasticity of skin.
Background
With age, the pulling action on the contoured skin in front of the ear will also result in a wrinkled appearance of the corresponding area. The fear of postoperative pain and the influence of postoperative recovery period on life and work are hindered, and people need a beautifying technique with small wound, quick recovery and long effective period. At present, the traditional operation mode of operation that the beauty treatment method that most plastic institutions adopted all selected to start from drawing the skin, and traditional operation result causes permanent neural paralysis to can produce facial nerve injury, and in addition, the wound causes hematoma, wound infection greatly easily, can produce certain damage to ear front profile skin, and consequently, how to improve ear front profile and remold is one of the cosmetic key points of treatment.
Nowadays, a cosmetic technique of injecting a substance to a local part of a human body has been clinically proven to have a safe treatment, and a cosmetic method for beauty loved people can be provided by having an obvious effect on the correction of wrinkles, depressions and scars of soft tissues of the face by injection. The key of injection beauty treatment is 'injection material' and 'beauty treatment injection method', collagen hyperplasia is stimulated by a specified position through a tissue filler, the beauty regeneration effects of wrinkle removal, cheek enlargement and whole face lifting are gradually achieved, and the tissue filler is metabolized into neutral and nontoxic water and carbon dioxide in a human body.
An effective solution to the problems in the related art has not been proposed yet.
Disclosure of Invention
Aiming at the problems in the related art, the invention provides a cosmetic injection method adopting injection pulling in front of ears, which aims to overcome the technical problems in the prior related art.
Therefore, the invention adopts the following specific technical scheme:
a cosmetic injection method adopting injection lifting in front of ears comprises the following steps:
s1, cleaning the front outline of the ear and completing the standard operation process;
s2, dividing the front outline of the ear by adopting the linear principle of a triaxial oblique tangent plane;
s3, preparing a composite degradable high molecular polymer carrier;
s4, injecting a composite degradable high polymer carrier to the treatment position of the front outline of the left ear and the front outline of the right ear in a beveling insertion needle way;
when the compound degradable high molecular polymer carrier in S4 is injected, the compound degradable high molecular polymer carrier is uniformly pushed into the subcutaneous tissue of human skin at an angle of 30 to 40 degrees by obliquely cutting the needle head at each axis point on both sides of the preset direction, and the needle head uses a blunt needle mode.
Further, the standard procedure of cleaning the front outline of the ear and completing the operation in S1 further includes the following steps:
s11, cleaning the facial contour skin with clear water;
s12, massaging the facial contour skin;
s13, after cleaning, dividing the outline of the face into left and right symmetry and carrying out aseptic disinfection;
s14, sterilizing the injection part by using medical alcohol carrier before injection.
Furthermore, when the ear front contour is divided by adopting the principle of three-axis diagonal tangent line shape in the step S2, the ear front contour is divided into six area axis points of a left-right symmetrical area a, an area B, an area C, an area D, an area E and an area F.
Further, when the composite degradable high molecular polymer carrier is configured in S3, the composite degradable high molecular polymer carrier includes a polymeric tissue filler component and a synergist, and the polymeric tissue filler component and the synergist are uniformly mixed in a formula ratio by using a dispersion medium liquid.
Further, the polymeric tissue bulking agent component comprises sodium hyaluronate and poly-L-lactic acid.
Furthermore, the synergist comprises sodium hydroxymethyl cellulose, mannitol, aloe polysaccharide, glycerol, amino acid, peptide, vitamins and growth factors.
Further, the step of injecting the compound degradable high polymer carrier to the treatment site of the anterior profile of the left ear by means of the obliquely-cut insertion needle in S4 further comprises the following steps:
two common needle points extending outwards from the outer canthus level along the position end of the area A and injecting 0.2ml to 0.4ml of composite degradable high molecular polymer carrier uniformly into the area A in a preset direction;
a position end along the area A and downwards along the area B, wherein the position end is divided into needle inlet points at 1 cm below a hairline and an ear front edge, and 0.3ml to 0.5ml of the composite degradable high polymer carrier is uniformly injected into the area B in a preset direction;
and (3) downwards along the position end of the zone C along the zone B, taking the position end at the tragus as a needle inserting point, and uniformly injecting 0.2ml to 0.4ml of the composite degradable high polymer carrier into the zone C in a preset direction.
Further, the step of injecting the compound degradable high polymer carrier to the treatment site of the anterior contour of the right ear by means of the obliquely-cut insertion needle in S4 further comprises the following steps:
two common needle points extending outwards from the outer canthus level of the eye along the position end of the D area and 0.2ml to 0.4ml of composite degradable high molecular polymer carrier is injected uniformly into the D area along a preset direction;
a position end along the area E downwards along the area D, wherein the position end is divided into needle inlet points at 1 cm below the hairline and the ear front edge, and 0.3ml to 0.5ml of the composite degradable high polymer carrier is uniformly injected into the area E in a preset direction;
and (3) a position end along the F zone downwards along the E zone, wherein the position end is a needle insertion point at the tragus, and 0.2ml to 0.4ml of the composite degradable high polymer carrier is uniformly injected into the F zone in a preset direction.
Furthermore, the composite degradable high molecular polymer carrier exists in the subcutaneous tissue of human skin in the form of gel medium.
Further, in S4, after injecting the compound degradable high polymer carrier to the treatment site of the left ear anterior contour and the right ear anterior contour by means of the oblique insertion needle, the method further comprises the following steps:
in the area of the treatment position, whether intravascular injection occurs when the compound degradable high molecular polymer carrier is injected or not is noticed, and if yes, hyaluronic acid degrading enzyme is immediately injected, and the emergency observation of hospitalization procedures is started.
The invention has the beneficial effects that:
(1) the invention provides a cosmetic injection method adopting injection pulling in front of the ear, which is specifically provided by the invention, and is assisted by the principle of triaxial oblique tangent plane linearity, and is injected into subcutaneous tissues of the outline in front of the ear by technical safety of medical practitioners, and each point position is uniformly provided with a composite high molecular polymer carrier, so that the pulling effect of immediately improving the statute lines and puppet lines and changing the relaxation can be achieved, and more wound lacerations are not needed.
(2) The invention provides a solution that the prior art is difficult to realize deep maintenance and nursing of the contour skin in front of the ear, compared with other filling injections, the composite degradable high molecular polymer carrier is milder, does not have any reaction of allergy and silting, can not only effectively pull and lift, but also fill the dents of cheeks withered due to aging, beautifies the appearance, has 100 percent of biocompatibility and biodegradability, is safer and more effective, the tissue filler is metabolized into neutral and nontoxic water and carbon dioxide in a human body, which has important practical significance for realizing the development of social medical beauty treatment safety modernization, and the neutral and nontoxic tissue filler is injected into subcutaneous tissues through a needle head to achieve the lasting supporting effect of pulling and tightening the front outline of the ear, and the curative effect can be maintained for about 1 year and half to 2 years.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without creative efforts.
Fig. 1 is a schematic flow diagram of a cosmetic injection method using an injection puller in front of the ear according to an embodiment of the invention;
FIG. 2 is a flowchart of a technical means of a cosmetic injection method using an injection puller in front of the ear according to an embodiment of the present invention;
fig. 3 is a second technical means flowchart of a cosmetic injection method using an injection puller in front of the ear according to an embodiment of the present invention.
Detailed Description
For further explanation of the various embodiments, the drawings which form a part of the disclosure and which are incorporated in and constitute a part of this specification, illustrate embodiments and, together with the description, serve to explain the principles of operation of the embodiments, and to enable others of ordinary skill in the art to understand the various embodiments and advantages of the invention, and, by reference to these figures, reference is made to the accompanying drawings, which are not to scale and wherein like reference numerals generally refer to like elements.
According to the embodiment of the invention, the cosmetic injection method adopting the injection pulling in front of the ear is provided, and the composite degradable high polymer carrier with good biocompatibility is matched, so that the composite degradable high polymer carrier is milder compared with other filling injection solutions, and has very important significance for injection and cosmetic.
The present invention will now be further described with reference to the accompanying drawings and detailed description, wherein as shown in fig. 1-3, a cosmetic injection method using an injection puller in front of the ear according to an embodiment of the present invention comprises the steps of:
s1, cleaning the front outline of the ear and completing the standard operation process;
wherein, the standard procedure of cleaning the front outline of the ear and completing the operation in S1 further comprises the following steps:
s11, cleaning the facial contour skin with clear water;
s12, massaging the facial contour skin;
s13, after cleaning, dividing the outline of the face into left and right symmetry and carrying out aseptic disinfection;
s14, sterilizing the injection part by using medical alcohol carrier before injection.
S2, dividing the front outline of the ear by adopting the linear principle of a triaxial oblique tangent plane;
when the ear front contour is divided by adopting the principle of three-axis diagonal plane line shape in S2, the ear front contour is divided into six area axis points of a left area A, a right area B, a left area C, a right area D, a left area E and a right area F which are symmetrical.
S3, preparing a composite degradable high molecular polymer carrier;
when the composite degradable high molecular polymer carrier is prepared in S3, the composite degradable high molecular polymer carrier includes a polymeric tissue filler component and a synergist, and the polymeric tissue filler component and the synergist are uniformly mixed in a formula ratio by using a dispersion medium (physiological saline). Is milder than other filling injections, and injects the beauty injection liquid to the axial point of the outline in front of the ear.
The polymeric tissue filler comprises sodium hyaluronate and poly-L-lactic acid.
The synergist comprises sodium hydroxymethyl cellulose, mannitol, aloe polysaccharide, glycerol, amino acids, peptide, vitamins and growth factor.
S4, injecting a composite degradable high polymer carrier to the treatment position of the front outline of the left ear and the front outline of the right ear in a beveling insertion needle way;
wherein, when injecting the compound degradable high molecular polymer carrier in S4, the compound degradable high molecular polymer carrier is slowly pushed into the subcutaneous tissue of human skin by obliquely cutting the needle head at an angle of 30 to 40 degrees at each axial line point at two sides of the arrow direction in the figures 2 and 3, the needle is withdrawn, the drug is slowly administered, the drug is properly adjusted and shaped after the needle is withdrawn, and the massage is gently carried out until the layering part is finished; the needle holes are not sewed, the erythromycin ointment is coated outside, the postoperative swelling is reduced, and the needle head adopts a blunt needle mode, so that the effects of improving skin wrinkles and increasing the elasticity of skin are achieved. In the step S4, injecting the compound degradable high molecular polymer carrier to the treatment position (actual line position) of the front profile of the left ear by means of inserting a needle head obliquely, further comprises the following steps:
along the position end of region A, the two points extending outward from the outer canthus level of the eye are needle insertion points, and 0.2ml to 0.4ml of the compound degradable high molecular polymer carrier is injected uniformly into region A in the direction of the arrow in fig. 2;
a position end along the area A and downward along the area B, wherein the position end is divided into needle inlet points at 1 cm below the hairline and the ear front edge, and 0.3ml to 0.5ml of the composite degradable high polymer carrier is uniformly injected into the area B in the arrow direction in the figure 2;
along the position end of the B zone and downward along the C zone, the position end is a needle-inserting point at the tragus, and 0.2ml to 0.4ml of the composite degradable high molecular polymer carrier is uniformly injected into the C zone along the arrow direction in the figure 2.
S4, the injection of the compound degradable high polymer carrier to the treatment position (actual line position) of the front outline of the right ear by the way of inserting the needle head in a bevel cutting way further comprises the following steps:
along the position end of region D, the two points extending outward from the outer canthus level of the eye are needle insertion points, and 0.2ml to 0.4ml of the compound degradable high molecular polymer carrier is injected uniformly into region D in the direction of the arrow in fig. 3;
a position end along the D area and downward along the E area, wherein the position end is divided into needle inlet points at 1 cm below the hairline and the ear front edge, and 0.3ml to 0.5ml of the composite degradable high polymer carrier is uniformly injected into the E area in the arrow direction in the figure 3;
and (3) injecting 0.2ml to 0.4ml of the composite degradable high molecular polymer carrier into the region F along the position end of the region E downwards along the region F, wherein the position end is a needle inlet point at the tragus, and the arrow direction in the figure 3 is used for uniformly injecting the composite degradable high molecular polymer carrier into the region F.
The composite degradable high molecular polymer carrier exists in the subcutaneous tissue of human skin in the form of gel medium.
S4, the method for injecting the compound degradable high polymer carrier to the treatment position of the front outline of the left ear and the front outline of the right ear by the way of inserting the needle head obliquely further comprises the following steps:
in the area of the treatment position, whether intravascular injection occurs when the compound degradable high molecular polymer carrier is injected or not is noticed, and if yes, hyaluronic acid degrading enzyme is immediately injected, and the emergency observation of hospitalization procedures is started.
In conclusion, the invention provides a cosmetic injection method by adopting injection pulling in front of the ear, which is combined with the principle of triaxial diagonal section line shape, and is injected into the subcutaneous tissue of the outline in front of the ear by a medical practitioner with skill and safety, and each point is uniformly provided with a composite high molecular polymer carrier, so that the pulling effect of immediately improving the statute lines and the puppet lines and changing the looseness can be achieved, and more wound lacerations are not needed. The invention provides a solution that the prior art is difficult to realize deep maintenance and nursing of the contour skin in front of the ear, compared with other filling injections, the composite degradable high molecular polymer carrier is milder, does not have any reaction of allergy and siltation, can not only effectively pull up, but also fill up the cheek depression which is atrophied due to aging, beautifies the appearance, has 100 percent of biocompatibility and biological decomposability, is safer and more effective, the tissue filler is metabolized into neutral and nontoxic water and carbon dioxide in a human body, which has important practical significance for realizing the development of social medical beauty treatment safety modernization, and the neutral and nontoxic tissue filler is injected into subcutaneous tissues through a needle head to achieve the lasting supporting effect of pulling and tightening the front outline of the ear, and the curative effect can be maintained for about 1 year and half to 2 years.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (10)
1. A cosmetic injection method adopting injection pulling in front of ears is characterized by comprising the following steps:
s1, cleaning the front outline of the ear and completing the standard operation process;
s2, dividing the front outline of the ear by adopting the linear principle of a triaxial oblique tangent plane;
s3, preparing a composite degradable high molecular polymer carrier;
s4, injecting a composite degradable high polymer carrier to the treatment position of the front outline of the left ear and the front outline of the right ear in a beveling insertion needle way;
when the compound degradable high molecular polymer carrier in S4 is injected, the compound degradable high molecular polymer carrier is uniformly pushed into the subcutaneous tissue of human skin at an angle of 30 to 40 degrees by obliquely cutting the needle head at each axis point on both sides of the preset direction, and the needle head uses a blunt needle mode.
2. The method as claimed in claim 1, wherein the standard procedure of cleaning and completing the anterior ear contour in S1 further comprises the following steps:
s11, cleaning the facial contour skin with clear water;
s12, massaging the facial contour skin;
s13, after cleaning, dividing the outline of the face into left and right symmetry and carrying out aseptic disinfection;
s14, sterilizing the injection part by using medical alcohol carrier before injection.
3. The method according to claim 1, wherein the division of the anterior auricular contour in S2 using the principle of diagonal alignment of three axes divides the anterior auricular contour into six axial loci of bilaterally symmetric regions a, B, C, D, E and F.
4. The method as claimed in claim 1, wherein when the compound degradable polymer carrier is disposed in S3, the compound degradable polymer carrier comprises a polymeric tissue filler component and a synergist, and the polymeric tissue filler component and the synergist are uniformly mixed by a dispersion medium.
5. The method of claim 4, wherein the polymeric tissue filler comprises sodium hyaluronate and poly-L-lactic acid.
6. The method of claim 4, wherein the potentiating agent comprises sodium carboxymethylcellulose, mannitol, aloe vera polysaccharide, glycerin, amino acids, peptides, vitamins and growth factors.
7. The method of claim 1, wherein the step of injecting the degradable polymer carrier into the treatment site of the anterior profile of the left ear by means of the needle inserted at the oblique angle at S4 further comprises the steps of:
two common needle points extending outwards from the outer canthus level along the position end of the area A and injecting 0.2ml to 0.4ml of composite degradable high molecular polymer carrier uniformly into the area A in a preset direction;
a position end along the area A and downwards along the area B, wherein the position end is divided into needle inlet points at 1 cm below a hairline and an ear front edge, and 0.3ml to 0.5ml of the composite degradable high polymer carrier is uniformly injected into the area B in a preset direction;
and (3) downwards along the position end of the zone C along the zone B, taking the position end at the tragus as a needle inserting point, and uniformly injecting 0.2ml to 0.4ml of the composite degradable high polymer carrier into the zone C in a preset direction.
8. The method of claim 1, wherein the step of injecting the biodegradable polymer carrier into the treatment site of the anterior profile of the right ear by means of the needle inserted at the oblique angle at S4 further comprises the steps of:
two common needle points extending outwards from the outer canthus level of the eye along the position end of the D area and 0.2ml to 0.4ml of composite degradable high molecular polymer carrier is injected uniformly into the D area along a preset direction;
a position end along the area E downwards along the area D, wherein the position end is divided into needle inlet points at 1 cm below the hairline and the ear front edge, and 0.3ml to 0.5ml of the composite degradable high polymer carrier is uniformly injected into the area E in a preset direction;
and (3) a position end along the F zone downwards along the E zone, wherein the position end is a needle insertion point at the tragus, and 0.2ml to 0.4ml of the composite degradable high polymer carrier is uniformly injected into the F zone in a preset direction.
9. The method as claimed in claim 7 or 8, wherein the compound degradable high molecular polymer carrier is in the form of gel medium in the subcutaneous tissue of human skin.
10. The method of claim 1, wherein the injecting the biodegradable polymer carrier into the treatment site of the anterior left and right ear profiles by the insertion of the needle through the oblique cutting process at step S4 further comprises the following steps:
in the area of the treatment site, care was taken to see if an intravascular injection occurred while injecting the gel vehicle, and if so, hyaluronic acid degrading enzyme was immediately injected and a hospitalization procedure was initiated for emergency observation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210076346.4A CN114432541A (en) | 2022-01-24 | 2022-01-24 | Cosmetic injection method adopting injection and lifting in front of ears |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210076346.4A CN114432541A (en) | 2022-01-24 | 2022-01-24 | Cosmetic injection method adopting injection and lifting in front of ears |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114432541A true CN114432541A (en) | 2022-05-06 |
Family
ID=81370711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210076346.4A Pending CN114432541A (en) | 2022-01-24 | 2022-01-24 | Cosmetic injection method adopting injection and lifting in front of ears |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114432541A (en) |
-
2022
- 2022-01-24 CN CN202210076346.4A patent/CN114432541A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008072229A2 (en) | Methods for dermal filling using microneedles | |
| KR101236363B1 (en) | Particles for soft tissue augmentation | |
| US20060040895A1 (en) | Aesthetic use of hyaluronan | |
| US20090297632A1 (en) | Device, Methods and Compositions to Alter Light Interplay with Skin | |
| CN113648273B (en) | Soothing mask beneficial to postoperative recovery of facial skin repair and preparation method thereof | |
| CN113855930A (en) | A skin caring injection method for removing wrinkle and regenerating collagen by hand injection | |
| RU2135122C1 (en) | Method for producing skin rejuvenascence | |
| CN114432541A (en) | Cosmetic injection method adopting injection and lifting in front of ears | |
| JP2005306746A (en) | Wrinkle therapeutic agent for face | |
| CN113855931A (en) | Beautifying injection method for shaping eyebrows and lifting eyebrows | |
| CN114768001A (en) | Injection method for facial rejuvenation | |
| CN114452485A (en) | Beauty injection method for pulling, lifting, tightening and shaping face on hairline | |
| Passy | PMMA implants: a new way to correct body defects without surgery | |
| CN111544650B (en) | Method and device for preparing super-emulsified erosive fat | |
| CN114432544A (en) | Beauty injection method and skin regeneration beauty injection using multi-dimensional mesh line carving | |
| Pourang et al. | Microneedling in Clinical Practice: Cosmetic applications | |
| CN213406136U (en) | A restore apparatus for after line carving failure | |
| CN114404735A (en) | Beautifying injection method for eliminating neck wrinkles and beautifying injection for regenerating skin and assisting skin | |
| US20230020956A1 (en) | Twelve-dimensional barbed surgical thread | |
| RU2731527C1 (en) | Method for elimination of cicatrical skin changes | |
| US20220395455A1 (en) | Methods and processes for enhancing the aesthetic appearance of a face | |
| Wörle et al. | Aesthetic Dermatology | |
| CN114588405A (en) | Beauty injection method for eliminating multi-layer injection eye bags | |
| CN117547677A (en) | Method for repairing complications caused by unknown injection | |
| Bragatto et al. | Hyaluronic Acid for Nasolabial Folds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220506 |